Regeneron Pharmaceuticals Inc. (REGN) (REGN)
Sanofi (SAN) and won U.S. clearance for Zaltrap as a treatment for patients with advanced colorectal cancer who haven’t been helped by previous therapy.
The Food and Drug Administration approved the drug for use in combination with chemotherapy as a so-called second-line treatment for patients whose colorectal cancer has spread to other parts of the body, the agency said today in a statement. Regeneron also sells the medicine, known by the scientific name aflibercept, under the name Eylea to treat wet age-related macular degeneration, a condition that causes vision loss.
Read the full story: http://tinyurl.com/cu3d22j
Source: Bloomberg Businessweek
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen